Drug Trial Radar · NCT03066804
A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF Patients
Last checked: Nov 19, 2026Latest source record: Oct 11, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,572
Actual
Start
Aug 22, 2017
Primary completion
Oct 28, 2019
Study completion Oct 28, 2019
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Feb 28, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 45 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to demonstrate the superiority of LCZ696 over individualized medical therapy for comorbidities in reducing N-terminal pro-brain natriuretic peptide (NT-proBNP) and improving exercise capacity and HF symptoms in patients with heart failure with preserved ejection fraction (HFpEF).
Conditions
- Heart Failure With Preserved Ejection Fraction
Interventions
sacubitril/valsartanDrug
Sacubitril/valsartan is available as 24 mg/26 mg, 49 mg/51 mg, 97 mg/103 mg, respectively in tablet form to be taken orally
EnalaprilDrug
Enalapril is available as 2.5 mg, 5 mg, and 10 mg tablet form to be taken orally
ValsartanDrug
Valsartan is available as 40 mg, 80 mg, 160 mg tablet form to be taken orally
Placebo to match sacubitril/valsartanDrug
Placebo to match LCZ696 50 mg, 100 mg, 200 mg tablet form to be taken orally
Placebo to match enalaprilDrug
Placebo to match enalapril 2.5 mg, 5 mg, 10 mg tablet form to be taken orally
Placebo to match valsartanDrug
Placebo to match valsartan 40 mg, 80 mg, 160 mg tablet form to be taken orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in N-terminal Pro-brain Natriuretic Peptide (NT-proBNP) at Week 12Time frame: Baseline, week 12
- Change From Baseline in 6 Minute Walk Distance (6MWD) at Week 24Time frame: Baseline, week 24
Locations
380 sites in 32 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Andalusia, Alabama
Novartis Investigative Site
Mobile, Alabama
Novartis Investigative Site
Beverly Hills, California
Novartis Investigative Site
Long Beach, California
Novartis Investigative Site
Santa Ana, California
Novartis Investigative Site
Sylmar, California
Novartis Investigative Site
Aurora, Colorado
Novartis Investigative Site
Stamford, Connecticut
Novartis Investigative Site
Bradenton, Florida
Novartis Investigative Site
Gainesville, Florida
Novartis Investigative Site
Hollywood, Florida
Novartis Investigative Site
Miami, Florida
Novartis Investigative Site
Port Orange, Florida
Novartis Investigative Site
Thomasville, Georgia
Novartis Investigative Site
Arlington Heights, Illinois
Novartis Investigative Site
Alexandria, Louisiana
Novartis Investigative Site
Chalmette, Louisiana
Novartis Investigative Site
Houma, Louisiana
Novartis Investigative Site
Boston, Massachusetts
Novartis Investigative Site
Lincoln, Nebraska
Novartis Investigative Site
Omaha, Nebraska
Novartis Investigative Site
Rochester, New York
Novartis Investigative Site
Marion, Ohio
Novartis Investigative Site
Corvallis, Oregon
Novartis Investigative Site
Abington, Pennsylvania
Novartis Investigative Site
Sioux Falls, South Dakota
Novartis Investigative Site
Jackson, Tennessee
Novartis Investigative Site
Dallas, Texas
Novartis Investigative Site
Lufkin, Texas
Novartis Investigative Site
Tomball, Texas
Novartis Investigative Site
Falls Church, Virginia
Novartis Investigative Site
Seattle, Washington
Novartis Investigative Site
Buenos Aires, Argentina
Novartis Investigative Site
Córdoba, Argentina
Novartis Investigative Site
Córdoba, Argentina
Novartis Investigative Site
Córdoba, Argentina
Novartis Investigative Site
Córdoba, Argentina
Novartis Investigative Site
Córdoba, Argentina
Novartis Investigative Site
Formosa, Argentina
Novartis Investigative Site
San Luis, Argentina
Showing 40 of 380 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.